Insider · CIK 0001952920
Greg Pyszczymuka
Files at AYTU (AYTU BIOPHARMA, INC), EVOK (Evoke Pharma Inc). First filing -, latest -.
Greg Pyszczymuka files SEC Form 4 as officer and director at AYTU (AYTU BIOPHARMA, INC), and also at EVOK (Evoke Pharma Inc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Greg Pyszczymuka has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 17, 2025 | EVOK Evoke Pharma Inc | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | EVOK Evoke Pharma Inc | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,155 | - | - | 0 | Dec 17, 2025 |
| Oct 3, 2025 | AYTU AYTU BIOPHARMA, INC | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 36,102 | Oct 7, 2025 |
| May 21, 2025 | EVOK Evoke Pharma Inc | AGrant or award Stock Option (Right to Buy)derivative | +1,155 | $0.00 | $0 | 6,988 | May 22, 2025 |
| Mar 31, 2025 | AYTU AYTU BIOPHARMA, INC | MOption exercise Common Shares | +209 | - | - | 23,602 | Mar 31, 2025 |
| Mar 31, 2025 | AYTU AYTU BIOPHARMA, INC | MOption exercise Restricted Stock Unitsderivative | -209 | $0.00 | $0 | 0 | Mar 31, 2025 |
| Feb 20, 2025 | EVOK Evoke Pharma Inc | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Feb 24, 2025 |
| Dec 31, 2024 | AYTU AYTU BIOPHARMA, INC | MOption exercise Common Shares | +208 | - | - | 23,393 | Jan 2, 2025 |
| Dec 31, 2024 | AYTU AYTU BIOPHARMA, INC | MOption exercise Restricted Stock Unitsderivative | -208 | $0.00 | $0 | 209 | Jan 2, 2025 |
| Nov 6, 2024 | AYTU AYTU BIOPHARMA, INC | AGrant or award Employee Stock Option (Right to Buy)derivative | +7,000 | $0.00 | $0 | 7,000 | Nov 8, 2024 |
Questions about Greg Pyszczymuka
Answered from the filings on this page, as of the latest one.
Is Greg Pyszczymuka buying or selling?
Greg Pyszczymuka has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Greg Pyszczymuka's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Greg Pyszczymuka has 0.
Where does Greg Pyszczymuka file Form 4?
Greg Pyszczymuka has filed Form 4 at AYTU (AYTU BIOPHARMA, INC) as Chief Commercial Officer; EVOK (Evoke Pharma Inc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.